EMEA-002925-PIP01-20-M01

Table of contents

Key facts

Active substance
Cilgavimab (AZD1061)
Therapeutic area
Infectious diseases
Decision number
P/0048/2022
PIP number
EMEA-002925-PIP01-20-M01
Pharmaceutical form(s)
Solution for injection/infusion
Condition(s) / indication(s)
  • Prevention or treatment of COVID-19
  • Treatment of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
  • Intramuscular use
  • Intravenous use
Contact for public enquiries
AstraZeneca AB

E-mail: paediatrics@astrazeneca.com
Tel. +46 8553 27591
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating